Key Takeaways
- IO Biotech has permanently closed operations after filing for bankruptcy, following rejection from the FDA.
- The company’s main product, Cylembio, failed to prove more effective than Merck’s Keytruda in a Phase 3 trial.
- Other biotech firms, including Lipella Pharmaceuticals and f5 Therapeutics, have also recently shut down, highlighting challenges in the sector.
Company Closure and Bankruptcy Filing
IO Biotech, a Danish biotechnology firm, has officially ceased operations and filed for bankruptcy, closing its doors after significant challenges. On March 31, the company submitted a filing to the Securities and Exchange Commission, marking the end of its journey. A trustee appointed by the Delaware bankruptcy court will now manage the liquidation of IO’s assets, officially noting the departure of its employees, executive team, and board of directors.
The troubles for IO Biotech began in September when the FDA urged the company not to move forward with the approval process for its cancer vaccine, Cylembio. The vaccine’s phase 3 trial did not outperform Merck & Co.’s widely used Keytruda in enhancing progression-free survival rates for patients with unresectable or metastatic melanoma. While the Cylembio trial was close to demonstrating statistical significance, the negative recommendation from the FDA left IO in a precarious situation.
Attempting to stay resilient, IO Biotech halved its workforce and sought to design another trial for Cylembio to meet the regulatory concerns raised by the FDA. However, the struggle continued, as further communications with the FDA yielded little success, and the anticipated meeting results in December remained undisclosed.
Financially, the situation was tense. By the end of September 2025, IO Biotech had approximately $31 million in available funds, but those reserves were only expected to sustain operations through the first quarter of 2026 without additional income or procedures. Facing dwindling resources and a lack of regulatory support, the company engaged a financial advisor in January to explore potential strategic alternatives, including further layoffs.
In a parallel development, the same day that IO Biotech announced its bankruptcy, Lipella Pharmaceuticals, based in Pittsburgh, also revealed its filing for bankruptcy. This firm was working on an anti-inflammatory mouthwash aimed at treating symptomatic oral lichen planus, a condition impacting mucous membranes in the mouth.
Moreover, the biotech landscape has seen multiple companies retracting from the market. f5 Therapeutics, another biotech firm, shut down earlier in the same month, with its CEO emphasizing the harsh realities faced by early-stage biotechnology companies in recent years. Notably, Nido Biosciences was the first to dissolve in 2023 after its small molecule treatment for a rare neurological disease failed during a phase 2 trial.
The collective shutdowns of these companies highlight ongoing difficulties in the biotechnology industry, marked by regulatory hurdles, financial pressures, and challenging market conditions that continue to impact new and existing players in the sector. The fate of IO Biotech serves as a cautionary tale as other biotech firms navigate a complex landscape fraught with uncertainty and competition.
The content above is a summary. For more details, see the source article.